EHMT2 and hepatocellular carcinoma: Although the in vivo tumor-inhibitory potential of targeting G9a using small-molecule inhibitors or shRNAs of G9a were documented in previous studies [19,21], the in vivo models used a subcutaneous xenograft model [19] or were injected with problematic HCC cell lines such as SMMC-7211 and BEL7402 [21].